Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HER2-pulsed DC1 Booster Vaccines in HER2-positive Breast Cancer
NCT03630809Phase 2Terminated
- Sponsor
- Moffitt Cancer Center
- Start
- Jan 2019
- Primary completion
- Apr 2022
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of HER2 DC1 vaccine in breast cancer, sponsored by Moffitt Cancer Center. Started Jan 2019; status: terminated.
02
Drugs
HER2 DC1 vaccine
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03630809.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03630809.